coronary artery disease (CAD) or acute coronary syndrome (ACS), including unstable angina (UA), non-ST-elevation myocardial infarction (NSTEMI), or ST-elevation myocardial infarction (STEMI)
Conditions
Interventions
None listed
Sponsors
Dokkyo Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Eligible studies included adult patients with CAD or ACS (UA, NSTEMI, STEMI). Study designs were randomized controlled trials, prospective cohort studies, or retrospective observational studies. The intervention group received PCSK9 inhibitors in addition to statin therapy, and the control group received statin monotherapy or statin plus placebo. Studies were required to assess coronary plaque characteristics at both baseline and follow-up using intravascular imaging modalities (IVUS, OCT, or NIRS). Studies without imaging evaluation or without sufficient data for quantitative synthesis were excluded.
Exclusion criteria
Exclusion criteria: Eligible studies included adult patients with CAD or ACS (UA, NSTEMI, STEMI). Study designs were randomized controlled trials, prospective cohort studies, or retrospective observational studies. The intervention group received PCSK9 inhibitors in addition to statin therapy, and the control group received statin monotherapy or statin plus placebo. Studies were required to assess coronary plaque characteristics at both baseline and follow-up using intravascular imaging modalities (IVUS, OCT, or NIRS). Studies without imaging evaluation or without sufficient data for quantitative synthesis were excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The changes in percent atheroma volume (PAV), fibrous cap thickness (FCT), and maximum lipid core burden index within 4 mm (maxLCBI4mm) from baseline to follow-up will be evaluated between the PCSK9 inhibitor group and the control group using an inverse variance random-effects meta-analysis. | — |
Countries
Japan
Contacts
Public ContactRyu Umezono
Dokkyo Medical University Department of Cardiovascular Medicine
Outcome results
None listed